These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29293676)

  • 21. Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study.
    Seo KI; Yun BC; Li WJ; Lee SU; Han BH; Park ET
    Clin Mol Hepatol; 2017 Mar; 23(1):74-79. PubMed ID: 28259115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
    Lo AO; Chan HL; Wong VW; Wong GL
    J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs).
    Sheridan DA; Neely RD; Bassendine MF
    Clin Res Hepatol Gastroenterol; 2013 Feb; 37(1):10-6. PubMed ID: 22959093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The beginning of the end: what is the future of interferon therapy for chronic hepatitis C?
    Feld JJ
    Antiviral Res; 2014 May; 105():32-8. PubMed ID: 24548815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correction: Chronic Hepatitis C Virus Infection Is Associated with the Development of Rheumatoid Arthritis: A Nationwide Population-Based Study in Taiwan.
    Su FH; Wu CS; Sung FC; Chang SN; Su CT; Shieh YH; Yeh CC
    PLoS One; 2016; 11(11):e0166508. PubMed ID: 27829054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correction: Comparison of Clinical Manifestations and Outcomes between Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma: Analysis of a Nationwide Cohort.
    PLOS ONE Staff
    PLoS One; 2015; 10(1):e0116652. PubMed ID: 25615935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies.
    Origa R; Ponti ML; Filosa A; Galeota Lanza A; Piga A; Saracco GM; Pinto V; Picciotto A; Rigano P; Madonia S; Rosso R; D'Ascola D; Cappellini MD; D'Ambrosio R; Tartaglione I; De Franceschi L; Gianesin B; Di Marco V; Forni GL;
    Am J Hematol; 2017 Dec; 92(12):1349-1355. PubMed ID: 28929515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].
    Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Rókusz L; Szalay F; Telegdy L; Tornai I; Werling K; Makara M
    Orv Hetil; 2015 Mar; 156(9):343-51. PubMed ID: 25702254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1].
    Park SH
    Korean J Gastroenterol; 2016 Mar; 67(3):127-31. PubMed ID: 26996181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Novel treatments for hepatitis C virus infection in chronic kidney disease].
    Fabrizi F; Messa P
    G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correction: Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort.
    Gomides APM; de Albuquerque CP; Santos ABV; Amorim RBC; Bértolo MB; Júnior PL; Santos IA; Giorgi RDN; Sacilotto NC; Radominski SC; Borghi FM; Guimarães MFBR; Pinto MRDC; Resende GG; Bonfiglioli KR; Silva HCD; Sauma MFLDC; Sauma ML; de Medeiros JB; Pereira IA; de Castro GRW; Brenol CV; Xavier RM; da Mota LMH; Pinheiro GDRC
    PLoS One; 2019; 14(4):e0215198. PubMed ID: 30947308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic outcome of 6198 interferon-naïve Egyptian patients with chronic hepatitis C: a real-life experience and lessons to be learned in DAAs' era.
    Zayed N; Gamal Eldeen H; Elmakhzangy H; Seif M; El-Akel W; Awad T; Esmat G; Mabrouk M
    J Viral Hepat; 2016 Jul; 23(7):506-11. PubMed ID: 26936687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Update on hepatitis C therapy. New drugs, treatment response monitoring and emergence of resistance].
    Chueca Porcuna N; Alvarez Estévez M; Parra Ruiz J; Hernández Quero J; García García F
    Enferm Infecc Microbiol Clin; 2013 Feb; 31 Suppl 1():40-7. PubMed ID: 23453230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correction: the inhibitory effects of anacardic Acid on hepatitis C virus life cycle.
    PLOS ONE Staff
    PLoS One; 2015; 10(3):e0122379. PubMed ID: 25806528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population.
    Ethgen O; Sanchez Gonzalez Y; Jeanblanc G; Duguet A; Misurski D; Juday T
    J Med Econ; 2017 Feb; 20(2):162-170. PubMed ID: 27590836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correction: Decreasing Hepatitis C Virus Infection in Thailand in the Past Decade: Evidence from the 2014 National Survey.
    Wasitthankasem R; Posuwan N; Vichaiwattana P; Theamboonlers A; Klinfueng S; Vuthitanachot V; Thanetkongtong N; Saelao S; Foonoi M; Fakthongyoo A; Makaroon J; Srisingh K; Asawarachun D; Owatanapanich S; Wutthiratkowit N; Tohtubtiang K; Yoocharoen P; Oota S; Vongpunsawad S; Poovorawan Y
    PLoS One; 2016; 11(5):e0152451. PubMed ID: 27191955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.
    Miyazaki R; Miyagi K
    Ther Apher Dial; 2016 Oct; 20(5):462-467. PubMed ID: 27098678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs).
    Scavone C; Sportiello L; Rafaniello C; Mascolo A; Sessa M; Rossi F; Capuano A
    Expert Opin Drug Saf; 2016 Dec; 15(sup2):85-100. PubMed ID: 27875916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.
    Colpitts CC; Baumert TF
    Viruses; 2016 Aug; 8(8):. PubMed ID: 27537906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.